Biomarkers for Lung Cancer Testing

Optimal Lung Cancer Treatment Requires Biomarker Testing

Biomarkers for lung cancer testing and biomarker testing are the subject of this important medical segment. Join Drs Gary Palmer and Deborah Morosini of Foundation Medicine as they share insight on the importance of testing and multidisciplinary coordination in its implementation and success. You’ll learn how this has had personal impact, and how the diagnosis and treatment of lung cancer is rapidly evolving. Learn how physicians are prolonging and improving the lives of cancer victims. Visit or

The Balancing Act

Biomarkers for Lung Cancer Testing

The diagnosis and treatment of advanced or metastatic lung cancer is changing

The diagnosis and treatment of advanced or metastatic lung cancer is changing…and, it’s becoming more and more apparent that it cannot be defined as just one disease but a collection of many.

Over the past several years “biomarkers,” which can help predict response to cancer therapies, have come to the forefront.

In other words, cancers may have different biomarkers, or switches, that promote tumor growth. These biomarkers can help healthcare providers determine the particular type of cancer that is present and subsequently what might be causing the tumor to grow. As such, knowledge about these biomarkers are changing the way many cancers are treated, including the addition of upfront biomarker testing and screening in the diagnosis process.

It is critical that the multidisciplinary team involved in the diagnosis and treatment of patients with lung cancer works together to ensure all patients are tested for key biomarkers and that the results are available quickly; ideally PRIOR to treatment decisions being made.

Just like in breast cancer, when one is diagnosed with advanced or metastatic non-small cell lung cancer (NSCLC), key biomarker information MUST be readily available before treatment begins. With this information on the tumor, physicians are then informed to help make the most appropriate treatment decisions for patients.

Biomarkers and biomarker testing…important elements in the fight against lung cancer. If you or someone you know have been diagnosed with NSCLC, please contact a physician with any questions about biomarkers and biomarker testing. Healthcare professionals can visit from Boehringer Ingelheim for more information.

Make sure to check out The Balancing Act® that aired on Lifetime TV on March 28th featuring Dr. Gary Palmer, an oncologist and Senior Vice President for Foundation Medicine, and pathologist Dr. Deborah Morosini, Vice President of Clinical Development at Foundation Medicine, patient advocate and sister of Dana Reeve, who joined the show to discuss this important health topic. Watch the show:

The Balancing Act®, Airing on Lifetime TV, Discusses Biomarker Testing in Lung Cancer


Media Contact:
O2 Media, Inc.
(954) 691-1102

The Balancing Act®, Airing on Lifetime TV, Discusses Biomarker Testing in Lung Cancer

Boehringer Ingelheim Sponsors Segment on March 21st Show to Help Raise Awareness of Biomarker Testing in Lung Cancer

(Pompano Beach, FL – PR.Com/CISION – March 20, 2014) Award-winning popular morning show The Balancing Act®, airing on Lifetime® TV, will feature a segment sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. to discuss biomarker testing in lung cancer on Friday, March 21 at 7:00 a.m. (ET/PT). Make sure to tune in as The Balancing Act hosts help jump start the day with animated conversation and trusted information to empower a woman’s life.

Don’t miss this featured segment taking center stage on The Balancing Act:

– Importance of Biomarker Testing in Lung Cancer Brought to You by Boehringer Ingelheim
The diagnosis of lung cancer is rapidly changing, as nearly a quarter of advanced non-small cell lung cancer patients have a biomarker that can help identify appropriate treatments. Join Drs. Gary Palmer and Deborah Morosini of Foundation Medicine as they share insights into a multidisciplinary healthcare provider approach to biomarker testing in lung cancer. Further, you’ll learn how biomarkers and biomarker testing are elements in the fight against lung cancer.

“BI is committed to providing healthcare professionals involved in the diagnosis and treatment of lung cancer with education about biomarker testing,” said Kevin Lokay, vice president and business unit head of oncology, Boehringer Ingelheim Pharmaceuticals, Inc. “By testing for biomarkers immediately following a lung cancer diagnosis, healthcare professionals will have the opportunity to identify a treatment regimen that is most appropriate for their patient’s particular cancer. Healthcare professionals can visit for more information.”

About Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research program to discover and develop innovative cancer treatments. Working in close collaboration with the international scientific community and a number of the world’s leading cancer centers, Boehringer Ingelheim’s commitment to oncology is underpinned by using advances in science to develop a range of targeted therapies for various solid tumors and hematological cancers. The current focus of late-stage research includes compounds in three areas: signal transduction inhibition, angiogenesis inhibition and cell-cycle kinase inhibition. The company is also evaluating a robust and growing pipeline of early-stage oncology compounds in areas including growth/survival signaling, immunotherapy and epigenetics.

For information about participating in a Boehringer Ingelheim clinical trial, please visit or call 1.866.725.7110. Healthcare providers interested in learning more about Boehringer Ingelheim clinical trials in oncology can visit for additional information.

For more information please visit

About The Balancing Act® airing on Lifetime Television
Now in its 6th year, The Balancing Act® continues to empower women in all aspects of their lives. The mission at The Balancing Act is simple – the show strives to help today’s modern woman balance it all by bringing them exceptional solutions to everyday problems. Entertaining, educational and trusted by women, viewers can tune in to America’s premier morning show The Balancing Act on weekday mornings at 7:00 am (ET/PT) airing on Lifetime television. For additional information or to view a segment visit:

For more information regarding O2 Media Inc. Branded Entertainment, Product Placement and TV Brand Integration go to:

Join the Conversation!
Like us on Facebook at:
Follow us on Twitter at:!/balancingacttv
Watch us on YouTube at:

  • Lea Hunt

    Oh my goodness, such important information for cancer prevention and detection. Thank you. I am sharing with my Facebook group.